Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00550368 · ClinicalTrials.gov registry record · NA

Clinical Experiment of Helicobacter Pylori Transmission

A NA study of Infection and Achlorhydria, sponsored by Stanford University.

Completed
Registry status
NA
Development phase
45
Enrollment target
1
Study location

NCT00550368: Completed NA study of Infection and Achlorhydria, sponsored by Stanford University.

NCT00550368 is a NA study of Infection and Achlorhydria that has completed, run by Stanford University. The registered enrollment target is 45 participants, below the 725-participant average among 41 other Infection trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00550368, a NA study of Infection and Achlorhydria, has completed, sponsored by Stanford University.

COMPLETED
Registry status
NA
Development phase
45 participants
Enrollment target
1
Study location

Study Summary

The study proposes to test whether chronic infection with Helicobacter pylori protects individuals from symptomatic infection with enteropathogenic E. coli. The study will also evaluate the effect of gastric acidity in this relationship.

Conditions Studied

Interventions

  • BIOLOGICAL Biological intervention: Enteropathogenic E. coli

Study Locations (1)

California

  • Stanford University School of Medicine - Stanford

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2005-08
Est. Completion 2009-04
Phase NA
Stanford University

1,744 total trials

What the finished NCT00550368 record still lists

NCT00550368 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 725-participant average among 41 other Infection trials with a reported enrollment target (94% lower).

The record links to 2 conditions, with Infection appearing as the primary indexed condition, and to 1 intervention - of which Biological intervention: Enteropathogenic E. coli is the first listed.

NCT00550368 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT00550368 about?

NCT00550368 is a clinical study titled "Clinical Experiment of Helicobacter Pylori Transmission". The study proposes to test whether chronic infection with Helicobacter pylori protects individuals from symptomatic infection with enteropathogenic E. coli. The study will also evaluate the effect of gastric acidity in this relationship.

What is the current status of trial NCT00550368?

This trial is currently completed. It is a NA study. The enrollment target is 45 participants. The study started on 2005-08. Estimated completion is 2009-04.

What conditions does trial NCT00550368 study?

This clinical trial studies the following conditions: Infection, Achlorhydria.

What interventions are being tested in trial NCT00550368?

The interventions under investigation include: Biological intervention: Enteropathogenic E. coli (BIOLOGICAL).

Who is sponsoring clinical trial NCT00550368?

This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00550368 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Infection

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00550368's enrollment target sits among peer trials

45 28th of 41 higher than 14 of 41 other Infection trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Infection trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00550368, the US trial registry maintained by the National Library of Medicine. NCT00550368 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.